GA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn’s Disease

“In the CALM (Effect of Tight Control Management on Crohn’s Disease) trial comparing a symptom-based therapeutic strategy with a biomarker-based strategy, the use of frequent biomarker measurement to guide therapy escalation was associated with improved patient outcomes over 2 years.14 The performance of serum and fecal biomarkers of disease activity, as well as robust determination of thresholds that can function as surrogates of endoscopic activity assessment, have not been examined comprehensively, leading to significant variability in clinical practice in optimal use of these biomarkers.”      MORE

Image Credit:   Gastroenterology